shutterstock-99132881-web
12 September 2013Patents

India recommends compulsory licence for anti-cancer drug

The Health Ministry in India has recommended that a compulsory licence (CL) is issued for the manufacture of Bristol-Myers Squibb’s (BMS) anti-cancer drug Sprycel (dasatinib), potentially opening the door to the sale of cheaper imitations.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk